Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation for relapsed or refractory high-risk neuroblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Allogeneic hematopoietic stem cell transplantation

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Neuroblastoma | Phase 2 | Status: WITHDRAWN